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Short-term integrated  
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with newly diagnosed thoracic 
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Abstract
Objectives: The main objective of this study is to determine the feasibility of recruiting and retaining 
patients recently diagnosed with thoracic cancer to a trial of short-term integrated rehabilitation; evaluate 
uptake of theoretically informed components targeting physical function, symptom self-management and 
participation; estimate sample size requirements for an efficacy trial.
Design: Parallel group randomized controlled feasibility trial.
Setting: Three U.K. hospitals.
Participants: Patients ⩽eight weeks of thoracic cancer diagnosis, Eastern Cooperative Oncology Group 
Performance Status 0–3, any cancer stage and treatment plan.
Interventions: Participants randomly allocated (1:1) to short-term integrated rehabilitation and standard 
care or standard care alone over 30 days.
Main measures: Primary: participant recruitment and retention, targeting ⩾30% of eligible patients 
enrolling and ⩾50% of participants reporting outcomes at 30 days. Secondary: intervention fidelity; 
missing data and performance of outcome measures for self-efficacy, symptoms, physical activity and 
health-related quality of life.
Results: Of 159 eligible patients approached, 54 (34%) were recruited. A total of 44 (82%) and 39 
(72%) participants reported outcomes at 30 and 60 days, respectively. Intervention fidelity was high. 
Rehabilitation was delivered across 3 (1–3) sessions over 32 (22–45) days (median (range)). Changes in 
clinical outcomes were modest but most apparent at 60 days for health-related quality of life: Functional 
Assessment of Cancer Therapy Lung Cancer score median (interquartile range) change 9.7 (−12.0 to 16.0) 
rehabilitation versus 2.3 (−15.0 to 14.5) standard care.
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Introduction
Worldwide, more people are diagnosed with lung 
cancer than any other cancer1 and the incidence of 
pleural mesothelioma continues to increase.2 The 
prevalence of distressing and disabling symptoms 
in these thoracic cancers is high.3,4 Most people are 
diagnosed with advanced disease1,2 but strive to 
maintain normality in daily life.5 Needs-based can-
cer rehabilitation is recommended from diagnosis 
to reduce the impact of cancer and its treatment on 
functional well-being and to promote independ-
ence.6 However, many people face difficulties 
accessing rehabilitation due to poor service provi-
sion, lack of clinician recognition of functional 
need6 and/or negative views of rehabilitation.7 
Although traditional exercise-based interventions 
are safe and potentially effective in this population, 
rates of uptake and completion in supervised pro-
grammes are generally low.8,9 Symptom manage-
ment interventions tend to be reactive, targeting 
patients with well-established symptoms.10 Indi-
vidualized proactive rehabilitation programmes to 
minimize the impact of thoracic cancer on partici-
pation in daily life are lacking. To overcome some 
of these issues, we have developed a model of 
short-term integrated rehabilitation drawing on the-
ories of illness,11,12 rehabilitation13 and behaviour 
change.14 Rehabilitation processes, components 
and outcomes were identified via systematic 
review15 and focus groups with patients, carers and 
healthcare professionals.16 A manual was produced 
to support delivery of the intervention by a trained 
rehabilitation practitioner (e.g. physiotherapist, 
occupational therapist or dietitian). Short-term inte-
grated rehabilitation aims to support people to self-
manage symptoms and immediate functional needs. 
It also aims to reduce sedentary time to minimize 
the onset of physical deconditioning. Strategies 
include maintaining or improving physical activity 
levels, fitness and participation in daily activities 
during cancer treatment and beyond.
Before testing the efficacy of short-term inte-
grated rehabilitation in a large-scale trial, we have 
undertaken this formal feasibility study. We aimed 
to (1) determine the feasibility of recruiting and 
retaining people with thoracic cancer to a trial of 
short-term integrated rehabilitation delivered in 
the period following diagnosis; (2) to evaluate 
uptake of theoretically informed, individually tai-
lored intervention components and (3) obtain data 
on the acceptability of selected outcome measures 
and (4) estimate sample size requirements for an 
efficacy trial.
Methods
A multicentre randomized controlled feasibility 
trial comparing the short-term integrated rehabilita-
tion service plus standard care to standard care took 
place between February 2018 and April 2019. The 
protocol was preregistered (ISRCTN 92666109). 
Ethical approved was granted by the London South 
East Research Ethics Committee (Ref 17/LO/1871). 
Reporting follows the CONSORT guidelines and 
the Template for Intervention Description and 
Replication (TIDieR) checklist. No changes were 
made to the design or methods following trial 
commencement.
Participants were recruited from thoracic oncol-
ogy, palliative care and respiratory clinics across three 
U.K. hospitals, two in London and one in Nottingham. 
Eligible participants were adults, within eight weeks 
of a clinical or histological diagnosis of primary lung 
Conclusion: A trial to examine efficacy of short-term integrated rehabilitation for people newly diagnosed 
with thoracic cancer is feasible. A sample of 336 participants could detect a meaningful effect on health-
related quality of life as the primary outcome.
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cancer (stage I–IV) or pleural mesothelioma (local or 
extensive), Eastern Cooperative Oncology Group 
Performance Status of 0–3 (Supplementary Appendix 
1)17 and the ability to respond to questions in written 
English (or availability of translators to support this). 
People already receiving specialist rehabilitation, or 
who had a coexisting progressive neurological condi-
tion (e.g. motor neurone disease), Eastern Cooperative 
Oncology Group Performance Status 4, not able to 
complete questionnaires due to cognitive impairment, 
or with a physician-estimated prognosis of less than 
one month were excluded. All participants gave writ-
ten informed consent in accordance with the Good 
Clinical Practice and the Declaration of Helsinki.
Following baseline assessment, conducted in hos-
pital outpatients, inpatients or home settings, partici-
pants were randomly allocated (1:1 at the individual 
level) using an independent Web-based randomiza-
tion system at the King’s Clinical Trials Unit, 
London, UK. A minimization algorithm was used to 
maintain balance in both the trial groups for recruit-
ment site, performance status (0–1 or 2–3) and 
disease stage (I–II or III–IV). Following randomiza-
tion, the Clinical Trials Unit informed trial staff via 
secure email. Research nurses, who arranged out-
come assessments using self-report mailed question-
naires, were informed of trial entry but not group 
allocation. Due to the nature of the intervention, it 
was not possible to maintain allocation blinding for 
participants and trial physiotherapists (J.B., M.M., 
L.F. and E.D.). The trial statistician (W.G.) was also 
blind to group allocation.
All participants received standard care provided 
by their hospital for their condition. This included 
surgical, oncology and supportive and palliative 
care services. No rehabilitation was routinely pro-
vided at two sites. One London site provided multi-
professional outpatient-based specialist rehabili- 
tation for patients attending oncology follow-up 
clinics with functional needs identified following 
screening. We planned to recruit participants who 
were not scheduled or able to attend these clinics 
within eight weeks of diagnosis.
Participants allocated to short-term integrated re- 
habilitation (Supplementary Figure 1) were offered 
up to three sessions with a rehabilitation practitioner 
(physiotherapists) over six weeks (trained by J.B.). 
As indicated during model development,16 a flexible 
delivery approach was used with appointments last-
ing up to 1 hour, in the hospital or home setting and 
scheduled according to participant preference. Where 
possible, first appointments were face to face. 
Subsequent appointments were face to face or by 
telephone according to practical considerations and 
participant preference. The intervention used a 
psychologically informed approach18 to identify 
immediate functional priorities and concerns, illness 
understandings and future expectations relating 
to functional well-being. An intervention manual 
(https://www.kcl.ac.uk/cicelysaunders/attachments/
permalink/Integrated-Short-term-Rehabilitation-for-
Thoracic-Cancer-Intervention-Manual) was used to 
standardize change processes19 but was unscripted 
to enable tailoring and adaptation of intervention 
components to meet the expected variation in func-
tion-related needs. Inter-vention components were 
selected as indicated and included personalized 
information about the impact of thoracic cancer on 
function and goal planning for symptom prevention 
and/or self-management, graded physical activity, 
home-based exercise and participation and perfor-
mance in activities of daily living.
Intervention components were delivered using 
behaviour change techniques14 to support receipt 
and enactment. Information booklets, handheld 
fans and walking aids were offered and provided to 
support delivery of intervention components. An 
individual goal-orientated action plan, developed in 
consultation with each participant and held by them, 
was reviewed and updated at each session to sup-
port enactment. Participants were sign-posted to 
local hospital, community-based, hospice and char-
itable services (i.e. local cancer support organiza-
tions) as indicated in the manual and where available 
for on-going support. Those wanting to pursue 
supervised exercise training to improve fitness were 
signposted to local exercise services. At discharge, 
a letter summarizing the participant’s rehabilitation 
intervention and discharge action plan was sent to 
the participant and copied to their multiprofessional 
team for follow-up and onward referrals.
Our primary feasibility outcomes were rates of 
participant enrolment and retention. Feasibility 
endpoints, established a priori, were defined as 
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⩾30% of eligible patients consenting to the trial 
and ⩾50% of enrolled participants completing 
clinical outcome measures at 30 days. Secondary 
feasibility objectives were number of rehabilitation 
contacts delivered over 30 days, fidelity of service 
delivery, including use of intervention components 
and onwards referral to local rehabilitation services 
and missing data on clinical outcome measures at 
30 and 60 days. Participant self-reported experi-
ences were assessed by self-reported questionnaire 
comprising four items on trial processes from a 
national experience survey20 and 10 items on satis-
faction with the intervention from the Functional 
Assessment of Chronic Illness Therapy Treatment/
Patient Satisfaction (version 4).21 Free-text com-
ments were also invited.
Clinical outcomes were assessed at baseline, 
30 and 60 days following randomization via self-
reported postal questionnaire. Higher scores are bet-
ter for all measures except the Integrated Palliative 
Outcome Scale and the Client Services Receipt 
Inventory. Symptoms and concerns were measured 
by the Integrated Palliative Outcome Scale (17 
items, total score 0–68);22 physical activity level by 
the Physical Activity Scale for the Elderly (28 items, 
0–400);23 health-related quality of life measured by 
the Functional Assessment of Cancer Therapy 
(FACT) − Lung (total 34 item, 0–136; FACT − Trial 
Outcome Index (21 items, 0–84); FACT − lung 
cancer subscale seven items, (0–28);24 EuroQoL 
EQ-5D-5L (index values −1 to 1, EQ-VAS 0–100);25 
and confidence measured by the Self-Efficacy 
Measure for Chronic Disease (6 items, 0–60).26 The 
Client Services Receipt Inventory27 was used to 
measure resource use relating to hospital and com-
munity services, including social care, informal care 
and equipment provision. No changes were made to 
outcome assessments during the trial.
As this trial was designed to assess the feasibil-
ity of testing the short-term integrated rehabilita-
tion intervention, a formal power calculation 
around an estimated effect size on clinical outcome 
was not appropriate. Sample sizes of 24–60 partici-
pants have been recommended for feasibility 
studies.28,29 We took a conservative approach and 
aimed to recruit up to 60 participants which would 
allow us to estimate feasibility parameters and 
outcomes with sufficient precision to inform a 
future sample size calculation.
Statistical analysis
Data were analysed using SPSS (version 24, Chicago, 
IL, USA) under intention-to-treat principles. 
Feasibility outcomes and baseline demographics 
were summarized using descriptive statistics. Data 
on treatment fidelity in the intervention group were 
extracted from case report forms using the Behaviour 
Change Technique Taxonomy (version 1)30 by a 
trained member of the research team (J.B.). Treatment 
receipt was defined as the participant receiving 1–3 
rehabilitation sessions comprising symptom man-
agement ± physical activity or exercise ± task per-
formance and participation interventions. Reasons 
for withdrawal or loss to follow-up from the trial 
were summarized and classified by attrition due to 
death (ADD), attrition due to illness (ADI) or attri-
tion at random (AaR).31 The proportions of partici-
pants missing each variable were summarized by 
group at each time point. All serious adverse events 
(SAEs) and adverse events (AEs) relating to the 
intervention were summarized. This trial did not aim 
to evaluate effectiveness; therefore, clinical out-
comes were described by trial group at baseline and 
both follow-up time points, using standard descrip-
tive statistics, without significance testing.
Results
Figure 1 shows participant flow through the trial. 
Between February 2018 and January 2019, 374 
patients were screened, of whom 159 (42%) were 
eligible and 54 (34%) were enrolled. An overall 
recruitment rate of 4.5 participants per month was 
achieved with 1–2 accruals per month at each site. 
Barriers to additional recruitment included person-
nel absences in the clinical and research teams and 
changes to site working practices, for example, 
availability of lung cancer nurse specialists and 
allocation of space in oncology clinics. Following 
randomization, 82% and 72% of participants 
returned follow-up outcome measures at 30 and 
60 days, respectively. Attrition was comparable 
across both groups. In the rehabilitation group, one 
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Figure 1. CONSORT flow diagram.
*Three participants in the intervention group and one in the standard care group who did not return data at 30 days, did return 
data at 60 days. ECOG PS = Eastern Cooperative Oncology Group Performance Status.
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participant withdrew before receiving the interven-
tion due to rapidly progressing disease and one was 
lost to follow-up after receiving one rehabilitation 
contact. In the standard care group two participants 
were lost to follow-up and one withdrew from the 
trial. Postal questionnaires from four participants 
who remained in the trial (three rehabilitation 
group and one standard care group) were not 
received at 30 days.
Participants had a median (range) age of 67 
(44–85) years and 35 (65%) were men. Most were 
retired or not employed (32/54, 60%) though some 
were on sick leave (14/54, 27%) or still working 
(7/54, 14%). Less than one-quarter of participants 
lived alone. The majority 37/54 (68%) had non–
small cell lung cancer (NSCLC), though small cell 
lung cancer (SCLC), pleural mesothelioma and 
neuroendocrine tumours were represented. A total 
of 39 (72%) participants had stage III–IV disease 
(27 metastatic), of whom more than half were 
scheduled for treatment with chemotherapy dou-
blet combinations. Group allocation differences in 
mesothelioma diagnosis and disease stage were 
noted (Table 1).
Overall engagement with the rehabilitation inter-
vention was high, and it was delivered according to 
protocol (Table 2). Across the 26 participants allo-
cated to the intervention group, 69 rehabilitation 
sessions were delivered with a median of three per 
participant. 21 (84%) participants accessed all three 
rehabilitation sessions. Two-thirds of rehabilitation 
sessions were delivered face to face in the home; 
others occurred in hospital outpatient settings with 
a single session delivered on a hospital inpatient 
unit. The median duration of the first session was 
1 hour and follow-up sessions, 45 minutes. Two par-
ticipants declined further sessions, as they per-
ceived no needs or were too busy with appointments, 
though both remained in the trial.
Most participants engaged with all core interven-
tion components; physical activity and exercise 
(24/25, 96%), symptom self-management (20/25, 
80%) and task performance/participation (20/25, 
80%). Interventions frequently accepted by partici-
pants were home-based exercise or physical activity 
programmes and self-management strategies for 
fatigue and breathlessness. Few participants reported 
current problems managing personal activities of 
daily living, though 20/25 (80%) and 16/25 (64%) 
were provided with strategies to support work/ 
leisure or domestic activities, respectively.
Regarding the use of behaviour change tech-
niques,14 ‘credible source’ and ‘information about 
health consequences’ were used to support inter-
vention delivery in all participants (Supplementary 
Table 1). Behaviour-change techniques relating to 
goal setting, action planning, feedback and self-
monitoring, instruction, practice and ‘verbal per-
suasion about capability’ were used with over 
three-quarters of participants. Strategies to reduce 
negative emotions supported intervention delivery 
and enactment of rehabilitation plans in 12/25 
(48%) participants. Nine interventions delivered 
(9/26, 36%) included ‘adding objects to the envi-
ronment’ (handheld fans and assistive devices), 
though restructuring of the physical and social 
environment did not take place. Evaluation of par-
ticipant enactment of rehabilitation plans was 
clearly documented in most follow-up sessions.
No SAEs related to the intervention occurred. 
Two participants died following disease progres-
sions, and seven participants were admitted to hos-
pital relating to disease and oncology treatments 
(disease progression n = 3; sepsis, anaemia, pulmo-
nary embolus, blocked stent, all n = 1). Six inter-
vention group participants reported transitional 
worsening of symptoms following exercise or 
walking activities, two reported delayed onset 
muscle soreness and one had a non-injurious fall 
from a bicycle.
Rates of missing data items in returned ques-
tionnaires were low (Supplementary Table 2). 
Postal questionnaires from four participants who 
remained in the trial were not received at 30 days. 
One participant engaged with the intervention, but 
outcome measures were not received.
The item most frequently missed were FACT − 
Lung item ‘satisfaction with sex life’ (50%) and 
items in the Client Services Receipt Inventory 
relating to personal care (45%) and rehabilitation 
services (physiotherapy, occupational therapy and 
dietitian, 27%–36%). The Physical Activity Scale 
for the Elderly questionnaire allocates a score of −1 
to a weighted domain containing missing items, so 
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Table 1. Participant baseline characteristics.
Variables Total N = 54 Standard care N = 28 Rehabilitation N = 26
Site:
 1 25 (46) 13 12
 2 18 (33) 9 9
 3 11 (20) 6 5
Age in years (range) 67 (44–85) 67 (44–85) 66 (46–83)
Gender
 Women 19 (35) 8 11
 Men 35 (65) 20 15
Ethnicity
 White British 42 (78) 25 17
 Caribbean/Indian/Bangladeshi/ 5 (9) 1 4
 African 7 (13) 2 5
Other white
 Diagnosis  
 NSCLC (adeno) 24 (44) 10 14
 NSCLC (squamous) 13 (24) 7 6
 SCLC 9 (17) 5 4
 Pleural mesothelioma 5 (9) 5 0
 Neuroendocrine 3 (6) 1 2
 Days from diagnosis (range) 44 (2–65) 43 (2–65) 44 (3–60)
Disease by each stage
 I 11 (20) 5 6
 II–IIIa 12 (22) 7 5
 IIIb 8 (15) 6 2
 IV 23 (43) 10 13
ECOG PS
 0–1 47 (87) 24 23
 2–3 7 (13) 4 3
Metastases
 None 27 (50) 16 11
 Local 6 (11) 3 3
 Distant 21 (39) 9 12
Comorbidities
 COPD/CVD 18 (34) 7 11
 Diabetes 10 (19) 4 6
 MSK/inflammatory arthritis 18 (33) 10 8
Smoking history
 Current 5 (9) 2 3
 Ex-smoker 40 (76) 23 17
 Never smoked 8 (15) 2 6
 Missing 1 (2) 1 0
Lives with
 Alone 12 (22) 4 8
 Spouse/partner 31 (57) 18 13
 Other family/other 11 (21) 6 5
(Continued)
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Variables Total N = 54 Standard care N = 28 Rehabilitation N = 26
Employment
 Employed 7 (14) 5 2
 Sick leave 14 (27) 4 10
 Retired/not employed 31 (60) 18 13
Self-reported previous physical activity
 Sedentary 13 (24) 8 5
 Mild 27 (50) 12 15
 Moderate 12 (22) 6 6
 Vigorous 2 (4) 2 0
Anticancer treatment (commenced or planned)
 Surgerya 13 (24) 4 8
 Chemotherapy doublet 22 (41) 15 7
 Radical radiotherapy ± chemotherapy 8 (15) 5 3
 Palliative chemoradiotherapy 6 (11) 2 4
 Targeted therapy/immunotherapyb 4 (7) 1 3
 Palliative radiotherapy 1 (2) 0 1
Baseline outcome measure scores
 IPOS 19.00 (1.03–28.0) 16.5 (13.0–27.8) 20.0 (12.8–28.3)
 PASE 74.0 (42.9–117.4) 61.8 (30.9–105.7) 97.3 (52.2–170.9)
 FACT-L 93.0 (79.4–104.3) 91.5 (80.6–105.8) 94.5 (76.0–104.0)
 FACT-LCS 17.0 (14.0–23.0) 19.5 (14.0–23.8) 16.5 (13.8–20.8)
 FACT-TOI 52.0 (44.75–63.25) 50.0 (45.3–62.8) 53.5 (39.8–62.8)
 SEMCD 6.7 (5.0–8.2) 6.4 (5.1–8.5) 6.8 (5.0–8.0)
 EQ-5D-5L Index value 0.76 (0.65–0.84) 0.77 (0.6–0.8) 0.8 (0.65–0.9)
 EQ VAS 67.5 (50.0–80.0) 70.0 (50.0–80.0) 62.5 (48.8–80.0)
Baseline characteristics: values are number (percentage) or median (IQR). NSCLC: non–small cell lung cancer; SCLC: small cell 
lung cancer; ECOG: Eastern Cooperative Oncology Group; COPD: chronic obstructive pulmonary disease; CVD: cardiovascular 
disease; MSK: musculo-skeletal disease; IPOS: Integrated Palliative Care Outcome Scale; PASE: Physical Activity Scale for the 
Elderly; FACT-L/TOI/LCS: Functional Assessment of Cancer Therapy − Lung/trial outcome index/lung cancer subscale; SEMCD: 
Self-Efficacy Measure for Chronic Disease.
aIncludes n = 2 surgery and chemotherapy.
bIncludes n = 1 immunotherapy and chemotherapy.
Table 1. (Continued)
all obtained questionnaires were scored despite 
missing items in 6 (14%) and 5 (13%) question-
naires at 30 and 60 days, respectively.
Trial participation satisfaction was high in both 
groups (median 12) with a wider range of scores in 
the standard care group. Free-text comments from 
15 participants described mostly positive experi-
ences. Two intervention and three standard care 
group participants felt the questionnaires were too 
long or hard to fill in. Two standard care participants 
were unhappy with group allocation. Satisfaction 
with the rehabilitation intervention was also high 
with a maximum obtainable median score of 27 
(range: 23–27). A total of 14 participants completed 
free-text comments describing the impact of the 
intervention and the involvement of family mem-
bers during intervention delivery. Participants val-
ued the practical advice and face-to-face contact, 
reporting that the experience had been ‘helpful’, 
‘useful’, ‘educational’ and ‘empowering’. Two 
would have preferred more sessions. Nine com-
mented that they valued involvement of a family 
member, while three reported feeling able to talk 
more freely without family member present.
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Table 2. Intervention fidelity.
Intervention variable N (%) unless 
stated
Rehabilitation providers oncology expertisea
 Band 7 physiotherapist level 4 2
 Band 8 physiotherapist level 3 1
Uptake and mode of rehabilitation
  Days to first session (range, 
target < 14)
7 (5–13)
  Days first to last session (range, 
target < 42)
32 (22–45)
Sessions received
 One 25 (96)
 Two 23 (88)
 Three 21 (84)
Duration of sessions in minutes (range)
 First 60 (60–80)
 Second 48 (35–61)
 Third 45 (33–60)
Face to face 55 (80)
 Home 37 (67)
 Hospital outpatient clinic 17 (31)
 Inpatients 1 (2)
 Telephone 14 (20)
Intervention procedures
 Symptom management strategies 20 (80)
  Physical activity/fitness strategies 
(including exercise)
24 (96)
  Task performance/participation 
strategies
20 (80)
Equipment provision
 Handheld fan 7 (28)
 Walking aids 2 (8)
 Perching stool 1 (4)
Rehabilitation plan
  Agreed and document provided 
to participant
25 (100)
  Shared with oncologist/
multidisciplinary team
24 (96)
Signposting
 Cancer centre rehabilitation 13 (52)
 Community-based exerciseb 5 (20)
 Community-based rehabilitation 3 (12)
 Hospice rehabilitation 3 (12)
 Palliative care team 1 (4)
Behaviour change techniquesc
 Goals and planning 24 (96)
 Feedback and monitoring 23 (92)
Intervention variable N (%) unless 
stated
 Social support 17 (68)
 Shaping knowledge 24 (96)
 Natural consequences 25 (100)
 Comparison of behaviours 23 (92)
 Associations 11 (44)
 Repetition and substitution 20 (80)
 Comparison of outcomes 25 (100)
 Regulation 12 (48)
 Antecedents 9 (36)
 Identity/self belief 21 (84)
aBased on ‘Improving supportive and palliative care for adults 
with cancer: The manual’. NICE 2004.32 pp.144–145.
bIncludes yoga, pilates, local cancer support organizations and 
walking groups.
cCategorised and ordered according to the behaviour change 
techniques taxonomy, version 1.14
Table 1. (Continued)
 (Continued)
Table 3 displays change in outcomes at 30 and 
60 days. Baseline scores (Table 1) were compara-
ble across both groups for all measures except the 
Physical Activity Scale for the Elderly, which indi-
cated the rehabilitation group were more physi-
cally active. Overall, participants were generally 
sedentary, reported moderate symptom burden 
(Integrated Palliative Outcome Scale, median 
(interquartile range (IQR)) score: 19 (13–28)) and 
reported having confidence to manage their disease 
(Self-Efficacy Measure for Chronic Disease 6.7 
(5.0–8.2)). Client Services Receipt Inventory data 
indicate that about half of all participants were 
receiving support with personal care.
Changes over time were modest at both time 
points and a large degree of heterogeneity was evi-
dent (Table 3). Change was most apparent for 
physical activity level and health-related quality of 
life. Changes in Physical Activity Scale for the 
Elderly scores were small in both groups at 30 and 
60 days, with slightly higher scores in the standard 
care group at 60 days (median (IQR) 1.6 (−10.7 to 
50.6)) and worsening scores for rehabilitation at 
60 days (−15.5 (−50.8 to 38.9)). This contrasted 
with health-related quality of life scores which 
favoured the rehabilitation group. At 60 days, 
FACT − Lung scores improved by a median of 9.7 
10 Clinical Rehabilitation 00(0)
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(−12.0 to 16.0) compared to 2.3 (−15.0 to 14.5) 
with standard care. Similarly, the FACT − Trial 
Outcome Index rehabilitation group scores 
improved by 6 (−12 to 15.0) as compared to 4.5 
(−13.0 to 9.8) with standard care. Despite compa-
rable reductions in the EQ-5D utility index in both 
groups, a small worsening in EQ-VAS median 
score was observed in the standard care group at 30 
and 60 days (−2.5 (−20.0 to 5.0) and −6.5 (−13.8 to 
8.8)) as compared to no change then a small 
improvement (0 (0–10) and 5.0 (−17.5 to 24.8)) in 
the rehabilitation group. Symptoms reduced by a 
small amount at 30 days in both groups though by 
60 days, scores had improved by a median (IQR) of 
−4.5 (−12.5 to 6.0) in the rehabilitation group and 
−2.1 (−8.0 to 4.0) in the standard care group.
Discussion
This trial has found that it is feasible to recruit and 
retain people newly diagnosed with thoracic cancer 
to a randomized controlled trial of short-term inte-
grated rehabilitation versus standard care. Data 
relating to recruitment, retention and engagement 
with the rehabilitation intervention suggest that the 
trial was well designed and implemented and that 
this model of rehabilitation is acceptable and acces-
sible for patients across a range of clinical and 
demographic characteristics. The primary feasibil-
ity outcomes were achieved: 34% of eligible par-
ticipants were recruited and 82% were retained on 
trial for 30 days.
Low baseline levels of physical activity indi-
cate that the sample was representative of the pop-
ulation.33 Engagement with the rehabilitation 
intervention and intervention fidelity was high. 
More than 96% of participants allocated to receive 
rehabilitation accessed at least one session of reha-
bilitation, and more than 75% accessed each of the 
three core intervention components. Low levels of 
missing data in the clinical outcomes suggest that 
measures were acceptable to participants and have 
potential to be used in a future trial (see supple-
mentary material). However, unclear or missing 
data in the self-reported Client Services Receipt 
Inventory domains relating to physiotherapy, 
occupational therapy, inpatient and outpatient 
rehabilitation meant that it was difficult to quan-
tify and evaluate access to rehabilitation services. 
Participants rarely completed number of contacts, 
duration of intervention or provided information 
to enable assessment of contamination.
The trial did not aim to test effectiveness, and 
inferential statistical tests were not conducted. It is 
however of interest that changes in median scores 
at day 30 and day 60 were higher in the rehabilita-
tion group for all measures except EQ-5D-5L index 
scores and Physical Activity Scale for the Elderly. 
Modest changes observed in clinical outcome 
measures were larger in FACT–Lung and EQ VAS. 
Changes in Physical Activity Scale for the Elderly 
scores were less than the minimally important dif-
ference for this population.23 During development 
work, confidence was identified as a key modifia-
ble factor regardless of participant disease stage or 
performance status;16 however, minimal changes 
were observed in Self-Efficacy Measure for 
Chronic Disease scores.
This theory-based model of short-term integrated 
rehabilitation differs from other rehabilitation inter-
ventions tested in people with thoracic cancer in key 
areas. It brings together strategies to optimize physi-
cal function, symptom self-management and partici-
pation in valued daily activities. Rehabilitation 
interventions delivered following diagnosis have the 
potential to minimize the impact of disease and treat-
ment-related symptoms, such as breathlessness and 
fatigue, on symptom experience, functional inde-
pendence in activities of daily living and quality of 
life.6 The majority of research studies focus on exer-
cise interventions for people on curative treatment 
pathways.9 Exercise was prescribed during short-
term integrated rehabilitation when participants were 
willing to engage, but if not, other rehabilitation 
components, including preventive strategies were 
used to optimize physical activity levels and to mini-
mize the onset of symptoms developing alongside 
physical deconditioning. Holistic breathlessness ser-
vices improve distress relating to refractory breath-
lessness10 but have not yet been tested in people 
mainly limited by exertional breathlessness, as 
reported by participants in this trial.
The trial has several strengths. First, we were 
able to recruit and retain participants with a diverse 
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range of demographic characteristics, disease stage 
and comorbidities on all thoracic cancer treatment 
pathways. The recruitment and retention rates indi-
cate that the trial design and research personnel 
were able to address some of the barriers influenc-
ing participation in rehabilitation and exercise-
based interventions in people with thoracic 
cancer.16,34 Few participants declined for reasons 
relating to rehabilitation being a burden or unnec-
essary as found in a large mixed-methods study, 
where receptiveness to rehabilitation was low 
across all participants with mild to severe levels of 
disability.7 Most participants in this trial declined, 
as they had too much going on or were not inter-
ested; findings congruent with previous studies. 
Although continuing with normal life following 
diagnosis is important to patients,5 it cannot be 
assumed that they will want to have any functional 
concerns met by health providers. Brown et al.35 
found that people with lung cancer may prefer to 
access functional support from their own family.
The trial has addressed uncertainties sur-
rounding the delivery of rehabilitation interven-
tions at a time when patients are coming to terms 
emotionally with their new life situation while 
undergoing a busy and potentially arduous 
oncology treatment schedule.36 As prioritized in 
trial development work,15,16 we were able to 
deliver and test an inclusive, flexible and tai-
lored model of rehabilitation to address the het-
erogeneity of functional need. The model of 
short-term integrated rehabilitation echoes effec-
tive and valued components of holistic breath-
lessness services. It was delivered by an expert 
provider, integrated with busy treatment sched-
ules and focused on participants’ immediate 
functional concerns and priorities.10
The comparability of groups at baseline indi-
cates that the randomization system and minimiza-
tion categories worked well. However, all 
mesothelioma participants were randomized to 
receive standard care. In view of the changing 
treatment options and outcomes dependent on his-
tological diagnosis, minimizing for diagnosis 
should be considered in a larger trial. Although the 
rehabilitation model was designed to be inclusive 
and accessible for participants with an Eastern 
Cooperative Oncology Group Performance Status 
of 0–3, it is disappointing that few disabled par-
ticipants were recruited with most participants 
having an Eastern Cooperative Oncology Group 
Performance Status 0–1. The performance status 
of those declining to participate was not always 
available, so it is not known if participants with a 
performance status of 2–3 were approached and 
declined or if they were not identified during 
screening. Recruitment strategies in future trials 
need to consider how this group may be better rep-
resented in the sample, for example, asking people 
with a performance status of 2–3 to review trial 
recruitment materials and processes.
The constraints of delivering the intervention in 
a feasibility trial meant that integration with other 
oncology services was harder to achieve than was 
anticipated. To optimize accessibility and to reduce 
participant burden, we aimed to deliver the inter-
vention alongside scheduled hospital appoint-
ments. This presented challenges as intervention 
providers were based off site, and scheduled hospi-
tal appointments were frequently booked or 
changed at short notice. Attendance at thoracic 
cancer multiprofessional team meetings across 
three sites was not possible with the available trial 
personnel. Changes in working practices at two 
hospital sites meant clinic space was not always 
available. In addition, some participants had gaps 
between appointments longer than the six-week 
intervention delivery period. Delivering the inter-
vention in the hospital setting was more achievable 
when participants were attending for daily radio-
therapy or weekly chemotherapy. Some partici-
pants treated with surgery lived too far for home 
visits and had no postoperative appointments 
within the trial period and were therefore unable to 
enroll in the trial. Other integration strategies were 
achieved. These included providing participants 
with a written rehabilitation plan which they were 
encouraged to share with other healthcare profes-
sionals involved in their care. A discharge letter 
summarizing the intervention and rehabilitation 
plan was sent to each participant on discharge and 
copied to their oncologist and case-notes.
The findings of this feasibility trial have impli-
cations for future research and clinical practice. 
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High levels of participant retention, intervention 
fidelity and rates of data completeness with few 
non-SAEs suggest that the trial processes, inter-
vention and outcome measures were acceptable to 
participants. Training members of the usual health-
care team in screening for and delivering the inter-
vention in a full trial should improve capacity to 
deliver the intervention alongside schedules 
appointments and reduce performance bias. The 
design of a full trial should consider how to reach 
participants with Eastern Cooperative Oncology 
Group Performance Status 2–3 and those living 
further away from the recruiting centres.
Identifying a primary outcome for trials of 
rehabilitation interventions in this population is 
challenging, limited in part by the availability of 
suitable measures.37 The findings suggest that the 
more discrete measures (physical activity and 
confidence) were not relevant to all participants. 
The inclusive approach to eligibility, heterogene-
ity of the population, bi-directionality of func-
tional trajectories, mean that the health-related 
quality of life measure is more able to capture the 
impact of the short-term integrated rehabilitation 
intervention and should be considered as primary 
outcomes for a future trial. This is in line with the 
findings of a recent trial of home-based rehabili-
tation for people with inoperable lung cancer. 
Edbrooke et al.37 observed significant improve-
ments in health-related quality of life and symp-
tom levels with no changes in the primary 
outcome, physical function as measured by the 
6-minute walking test.
An estimated sample size for a future trial was 
calculated based on the observed changes in FACT–
Lung. Assuming a difference of 6 points, which is 
similar to the point estimate of effect we observed, 
and allowing for 25% attrition, 336 participants 
would be required to reliably detect this difference 
(80% power, P = 0.05) in an efficacy trial.
If shown to be effective, this model of rehabili-
tation would provide proactive support around the 
time of diagnosis for people with thoracic cancer. 
It would provide a route to consecutively screen 
patients and shift the focus of rehabilitation 
towards self-management and maintaining rather 
than regaining function. Furthermore, it can 
contribute to the integration of rehabilitation into 
oncology services.
This study has found that it is feasible to 
deliver and test a new, theory-based model of 
rehabilitation that differs from exercise interven-
tions typically tested in people newly diagnosed 
with thoracic cancer. It is an inclusive interven-
tion which addresses the heterogeneity of func-
tional need and barriers to rehabilitation observed 
in people newly diagnosed with thoracic cancer. 
We were able to deliver and test the new model 
in a feasibility trial, and efficacy testing is now 
warranted.
Clinical messages
•• It is feasible to deliver and test short-
term integrated rehabilitation for tho-
racic cancer in a randomized controlled 
trial in the period following diagnosis.
•• A sample size of 336 would be needed 
to detect a clinically important differ-
ence in health-related quality of life in 
an efficacy trial.
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